Schrödinger receives $57M from Lilly's acquisition of co-founded Ajax Therapeutics

Schrödinger disclosed that it received approximately $57 million in cash following Eli Lilly's acquisition of Ajax Therapeutics, a company Schrödinger co-founded. The payment represents a return on Schrödinger's founding investment in Ajax and provides immediate cash to the company's balance sheet.

Schrödinger remains eligible for additional milestone-based payments tied to Ajax's future clinical and regulatory progress, though the filing does not specify the amounts or triggers for these milestones. For retail investors, this is a straightforward monetization event. The $57 million provides non-dilutive capital that could support Schrödinger's core drug discovery platform and operations.

The potential for additional milestone payments creates upside optionality tied to Ajax's development progress under Lilly's ownership, though the timing and probability of those payments remain uncertain. The transaction validates Schrödinger's ability to co-found and exit portfolio companies, a key element of its business model beyond software licensing.